12/26
09:26 am
bhvn
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise [Seeking Alpha]
High
Report
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise [Seeking Alpha]
12/26
07:40 am
bhvn
Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and More Stock Market Movers [Barron's]
High
Report
Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and More Stock Market Movers [Barron's]
12/26
07:34 am
bhvn
Biohaven defended despite depression trial setback [Seeking Alpha]
High
Report
Biohaven defended despite depression trial setback [Seeking Alpha]
12/26
07:17 am
bhvn
Biohaven (NYSE:BHVN) had its "market perform" rating reaffirmed by analysts at William Blair.
High
Report
Biohaven (NYSE:BHVN) had its "market perform" rating reaffirmed by analysts at William Blair.
12/26
07:17 am
bhvn
Biohaven (NYSE:BHVN) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
High
Report
Biohaven (NYSE:BHVN) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/26
07:17 am
bhvn
Biohaven (NYSE:BHVN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
High
Report
Biohaven (NYSE:BHVN) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
12/24
04:29 pm
bhvn
Biohaven's depression drug fails mid-stage trial, shares fall [Yahoo! Finance]
High
Report
Biohaven's depression drug fails mid-stage trial, shares fall [Yahoo! Finance]
12/24
01:57 pm
bhvn
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder [Yahoo! Finance]
Neutral
Report
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder [Yahoo! Finance]
12/24
01:00 pm
bhvn
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
Neutral
Report
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
12/20
10:22 am
bhvn
Biohaven (BHVN): Valuation Check After Encouraging BHV-1510 Immuno-Oncology Data at ESMO Congress [Yahoo! Finance]
Low
Report
Biohaven (BHVN): Valuation Check After Encouraging BHV-1510 Immuno-Oncology Data at ESMO Congress [Yahoo! Finance]
12/20
04:46 am
bhvn
Biohaven (BHVN) Is Down 5.9% After New BHV-1510 Combo Data - What's Changed [Yahoo! Finance]
Low
Report
Biohaven (BHVN) Is Down 5.9% After New BHV-1510 Combo Data - What's Changed [Yahoo! Finance]
12/11
07:22 am
bhvn
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress [Yahoo! Finance]
Medium
Report
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress [Yahoo! Finance]
12/11
07:00 am
bhvn
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
Medium
Report
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
12/3
07:19 am
bhvn
Biohaven (NYSE:BHVN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
Low
Report
Biohaven (NYSE:BHVN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.
11/29
02:38 pm
bhvn
Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost [Yahoo! Finance]
Medium
Report
Biohaven (BHVN): Assessing Valuation After Recent Share Price Boost [Yahoo! Finance]
11/26
06:04 am
bhvn
Biohaven (NYSE:BHVN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
Low
Report
Biohaven (NYSE:BHVN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
11/25
01:48 pm
bhvn
Biohaven (NYSE:BHVN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Biohaven (NYSE:BHVN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/20
01:57 pm
bhvn
Biohaven (NYSE:BHVN) had its price target lowered by analysts at JPMorgan Chase & Co. from $47.00 to $15.00. They now have an "overweight" rating on the stock.
Low
Report
Biohaven (NYSE:BHVN) had its price target lowered by analysts at JPMorgan Chase & Co. from $47.00 to $15.00. They now have an "overweight" rating on the stock.
11/18
01:34 pm
bhvn
Biohaven (NYSE:BHVN) had its price target lowered by analysts at Morgan Stanley from $54.00 to $26.00. They now have an "overweight" rating on the stock.
Low
Report
Biohaven (NYSE:BHVN) had its price target lowered by analysts at Morgan Stanley from $54.00 to $26.00. They now have an "overweight" rating on the stock.
11/16
10:26 pm
bhvn
William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth [Yahoo! Finance]
Low
Report
William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth [Yahoo! Finance]
11/15
07:05 pm
bhvn
Biohaven (BHVN): Assessing Valuation After $175 Million Stock Offering and FDA Setback [Yahoo! Finance]
Low
Report
Biohaven (BHVN): Assessing Valuation After $175 Million Stock Offering and FDA Setback [Yahoo! Finance]
11/13
06:52 pm
bhvn
Pfizer slashes stake in COVID vaccine partner BioNTech [Yahoo! Finance Canada]
Low
Report
Pfizer slashes stake in COVID vaccine partner BioNTech [Yahoo! Finance Canada]
11/13
03:18 pm
bhvn
Biohaven (NYSE:BHVN) had its price target lowered by analysts at Citigroup Inc. from $28.00 to $14.00. They now have a "buy" rating on the stock.
Neutral
Report
Biohaven (NYSE:BHVN) had its price target lowered by analysts at Citigroup Inc. from $28.00 to $14.00. They now have a "buy" rating on the stock.
11/12
03:58 pm
bhvn
Biohaven Q3 Earnings: Falling Back To Earth With A Thud [Seeking Alpha]
Low
Report
Biohaven Q3 Earnings: Falling Back To Earth With A Thud [Seeking Alpha]
11/12
07:35 am
bhvn
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares [Yahoo! Finance]
Medium
Report
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares [Yahoo! Finance]